Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kiadis Aims To Boost Stem Cell Transplant Market With Adjuvant Filing

Executive Summary

Kiadis Pharma hopes to tap into a $1bn-plus commercial opportunity with its lead product ATIR101 in the treatment of blood cancer. ATIR101 has just been filed in Europe on the strength of data from single dose Phase II trial; a Phase III trial to pursue US approval is ongoing.

You may also be interested in...



Phase III Beckons For Kiadis In Unmatched Bone Marrow Transplant Patients

Kiadis Pharma N.V. has presented positive data from its single dose Phase II trial with lead product ATIR101 for the treatment of blood cancers, clearing the way for the start of a randomized Phase III in the second half of the year. The trial met the primary endpoint of transplant-related mortality (TRM) at six months.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Topics

Related Companies

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel